Clinical evidence-based study of Mongolian medicine Guanxintong capsule in the treatment of myocardial infarction/myocardial fibrosis
- Conditions
- Myocardial infarction/myocardial fibrosis
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Voluntarily participate in clinical trials and sign informed consent;
(2) Age 18-80 years old (including the critical value), male and female;
(3) meet the diagnosis of acute ST elevation myocardial infarction (STEMI);
(4) Patients who clinically meet the indications for emergency revascularization and agree to concurrent emergency interventional therapy (PCI);
(5) Patients in accordance with Mongolian medicine diagnosis and syndrome differentiation of heart tingling (coronary heart disease) and sticky heart tingling;
(6) Serological or imaging indicators of myocardial fibrosis suggest changes in myocardial fibrosis.
(1) In addition to this disease, acute coronary syndrome (ACS) had occurred within the past 1 month;
(2) Patients with new cardiovascular and cerebrovascular disease within 6 months before screening and those requiring cardiac surgery within 3 months or during the trial period; Uncontrolled hypertension and blood sugar, according to the latest guidelines, refer to the criteria for hypertensive diabetes: systolic blood pressure =140mmhg and/or diastolic blood pressure =90mmhg (refer to the 2023 Chinese Guidelines for Hypertension Prevention and Treatment); If you have diabetes symptoms, add blood glucose =11.1mmol/L at any point or fasting blood glucose =7.0mmol/L or blood glucose =11.1mmol/L 2 hours after a 75g glucose load (refer to the ADA Guidelines 2024).
(3) Patients who cannot tolerate basic treatment such as standard antithrombotic therapy, or who cannot receive MRI examination for various reasons;
(4) Severe liver and kidney dysfunction (ALT > 3 times the normal value, Scr > 221µmol/L) and other serious diseases;
(5) Pregnant or lactating women or those who have a pregnancy plan; A suspected or clear allergy to the investigational drug;
(6) Use any medicine containing basically the same ingredients as this Mongolian medicine within 2 weeks;
(7) Subjects who have experienced thrombolysis (including PCI after thrombolysis failure);
(8) TIMI after PCI was less than 2.
Those who meet any one of the above criteria are excluded.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method